Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.

  title={Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.},
  author={Ian D. Pavord and Sally Lettis and Nicholas W Locantore and Steven J Pascoe and Paul W. Jones and Jadwiga A Wedzicha and Neil C. Barnes},
  volume={71 2},
OBJECTIVE We performed a review of studies of fluticasone propionate (FP)/salmeterol (SAL) (combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients with COPD, which measured baseline (pretreatment) blood eosinophil levels, to test whether blood eosinophil levels ≥2% were associated with a greater reduction in exacerbation rates with ICS therapy. METHODS Three studies of ≥1-year duration met the inclusion criteria. Moderate and severe exacerbation rates were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 47 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 68 extracted citations


Publications referenced by this paper.
Showing 1-10 of 24 references

Acute exacerbations of COPD: identification of biological clusters and their biomarkers

  • M Bafadhel, S McKenna, S Terry
  • Am J Respir Crit Care Med
  • 2011

Chronic obstructive pulmonary disease : management of chronic obstructive pulmonary disease in adults in primary and secondary care ( partial update ) , 2010

  • C Crim, PM Calverley, JA Anderson
  • 2008

Similar Papers

Loading similar papers…